Log in

Novartis News Headlines (VTX:NOVN)

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume11.21 million shs
Average Volume5.98 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Novartis (VTX NOVN) News Headlines

Source:
DateHeadline
Novartis (NVS) receives positive CHMP opinion for Beovu for treatment of wet AMD - StreetInsider.comNovartis (NVS) receives positive CHMP opinion for Beovu for treatment of wet AMD - StreetInsider.com
www.streetinsider.com - December 13 at 10:36 AM
BRIEF-Novartis Says It Gets Positive EMA Opinion On Macular Degeneration Treatment - ReutersBRIEF-Novartis Says It Gets Positive EMA Opinion On Macular Degeneration Treatment - Reuters
www.reuters.com - December 13 at 10:36 AM
Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD - GlobeNewswireNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD - GlobeNewswire
www.globenewswire.com - December 13 at 10:36 AM
BRIEF-Intec Pharma Provides Update On Novartis Feasibility And Option Agreement - ReutersBRIEF-Intec Pharma Provides Update On Novartis Feasibility And Option Agreement - Reuters
www.reuters.com - December 11 at 2:07 PM
Intec Pharma Provides Update on Novartis Feasibility and Option Agreement - PRNewswireIntec Pharma Provides Update on Novartis Feasibility and Option Agreement - PRNewswire
www.prnewswire.com - December 11 at 9:07 AM
Novartis AG (VTX:NOVN) Receives Average Recommendation of "Hold" from BrokeragesNovartis AG (VTX:NOVN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 10 at 3:07 AM
Novartis (NVS) says Kymriah demonstrated consistent efficacy and safety outcomes in US patients when used in real-world setting - StreetInsider.comNovartis (NVS) says Kymriah demonstrated consistent efficacy and safety outcomes in US patients when used in real-world setting - StreetInsider.com
www.streetinsider.com - December 9 at 11:26 PM
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting - PRNewswireNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting - PRNewswire
www.prnewswire.com - December 9 at 11:26 PM
BRIEF-Novartis Kymriah Demonstrates Consistent Efficacy And Safety Outcomes In US Patients When Used In Real-World Setting - ReutersBRIEF-Novartis Kymriah Demonstrates Consistent Efficacy And Safety Outcomes In US Patients When Used In Real-World Setting - Reuters
www.reuters.com - December 9 at 6:26 PM
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting - BenzingaNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting - Benzinga
www.benzinga.com - December 9 at 6:26 PM
Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 92 Price TargetDeutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 92 Price Target
www.americanbankingnews.com - December 9 at 10:39 AM
Novartis Issues Update On Its R&D Pipeline - Quick Facts - NasdaqNovartis Issues Update On Its R&D Pipeline - Quick Facts - Nasdaq
www.nasdaq.com - December 7 at 8:08 AM
Novartis (VTX:NOVN) PT Set at CHF 82 by JPMorgan Chase & Co.Novartis (VTX:NOVN) PT Set at CHF 82 by JPMorgan Chase & Co.
www.americanbankingnews.com - December 6 at 1:56 PM
U.S. FDA approves generic versions of Novartis blockbuster MS treatment - ReutersU.S. FDA approves generic versions of Novartis blockbuster MS treatment - Reuters
www.reuters.com - December 6 at 9:09 AM
Goldman Sachs Group Analysts Give Novartis (VTX:NOVN) a CHF 105 Price TargetGoldman Sachs Group Analysts Give Novartis (VTX:NOVN) a CHF 105 Price Target
www.americanbankingnews.com - December 6 at 8:50 AM
FDA OKs generic versions of Novartis Gilenya - Seeking AlphaFDA OKs generic versions of Novartis' Gilenya - Seeking Alpha
seekingalpha.com - December 5 at 11:11 PM
Novartis taps Amazon Web Services to improve the manufacturing process - Business InsiderNovartis taps Amazon Web Services to improve the manufacturing process - Business Insider
www.businessinsider.com - December 5 at 1:11 PM
Novartis CEO plans 80+ submissions for drug approvals through 2022 - NasdaqNovartis CEO plans 80+ submissions for drug approvals through 2022 - Nasdaq
www.nasdaq.com - December 5 at 8:10 AM
BRIEF-Novartis Starts Tender Offer For Medicines Company - ReutersBRIEF-Novartis Starts Tender Offer For Medicines Company - Reuters
www.reuters.com - December 5 at 8:10 AM
Novartis tender offer for The Medicines Company commences - GlobeNewswireNovartis tender offer for The Medicines Company commences - GlobeNewswire
www.globenewswire.com - December 5 at 8:10 AM
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day - GlobeNewswireNovartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day - GlobeNewswire
www.globenewswire.com - December 5 at 8:10 AM
Amazon Brings AI Expertise to Drug Industry in Novartis Pact - BloombergAmazon Brings AI Expertise to Drug Industry in Novartis Pact - Bloomberg
www.bloomberg.com - December 4 at 1:52 PM
Global Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com - Yahoo FinanceGlobal Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - December 3 at 6:36 PM
Chief Digital Officer strategies at Pfizer, CVS, Novartis - Business InsiderChief Digital Officer strategies at Pfizer, CVS, Novartis - Business Insider
www.businessinsider.com - December 3 at 12:01 PM
Roche Could Leapfrog Biogen And Novartis In SMA Market - Seeking AlphaRoche Could Leapfrog Biogen And Novartis In SMA Market - Seeking Alpha
seekingalpha.com - December 3 at 12:01 PM
Why Novartiss $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen - Motley FoolWhy Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen - Motley Fool
www.fool.com - December 2 at 3:45 PM
Novartis Deal for Heart Drug Hinges on Succeeding Where Rivals Struggle - The Wall Street JournalNovartis Deal for Heart Drug Hinges on Succeeding Where Rivals Struggle - The Wall Street Journal
www.wsj.com - November 29 at 7:46 AM
Novartiss $90 mln Swiss factory to help solve cell therapy bottleneckNovartis's $90 mln Swiss factory to help solve cell therapy bottleneck
www.nasdaq.com - November 29 at 12:36 AM
Novartiss $90 million Swiss factory to help solve cell therapy bottleneckNovartis's $90 million Swiss factory to help solve cell therapy bottleneck
finance.yahoo.com - November 28 at 2:30 PM
Novartis (VTX:NOVN) Given a CHF 86 Price Target by HSBC AnalystsNovartis (VTX:NOVN) Given a CHF 86 Price Target by HSBC Analysts
www.americanbankingnews.com - November 26 at 7:33 AM
Novartis (VTX:NOVN) Given a CHF 90 Price Target at Credit Suisse GroupNovartis (VTX:NOVN) Given a CHF 90 Price Target at Credit Suisse Group
www.americanbankingnews.com - November 25 at 2:16 PM
UBS Group Analysts Give Novartis (VTX:NOVN) a CHF 89 Price TargetUBS Group Analysts Give Novartis (VTX:NOVN) a CHF 89 Price Target
www.americanbankingnews.com - November 25 at 8:59 AM
Novartis (VTX:NOVN) Given a CHF 105 Price Target at Goldman Sachs GroupNovartis (VTX:NOVN) Given a CHF 105 Price Target at Goldman Sachs Group
www.americanbankingnews.com - November 25 at 6:42 AM
Novartis (VTX:NOVN) PT Set at CHF 100 by Jefferies Financial GroupNovartis (VTX:NOVN) PT Set at CHF 100 by Jefferies Financial Group
www.americanbankingnews.com - November 25 at 6:42 AM
Novartis shifts Shanghais focus from research to early developmentNovartis shifts Shanghai's focus from research to early development
www.nasdaq.com - November 18 at 8:57 AM
Novartis sickle-cell drug gets U.S. FDA approvalNovartis sickle-cell drug gets U.S. FDA approval
www.nasdaq.com - November 15 at 6:54 PM
European advisory group backs Novartis Isturisa and Mayzent - Seeking AlphaEuropean advisory group backs Novartis' Isturisa and Mayzent - Seeking Alpha
seekingalpha.com - November 15 at 8:53 AM
BRIEF-Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS - ReutersBRIEF-Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS - Reuters
www.reuters.com - November 15 at 8:53 AM
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk - Yahoo FinanceTop Analyst Reports for Microsoft, Novartis & Novo Nordisk - Yahoo Finance
finance.yahoo.com - November 14 at 12:42 AM
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace - Yahoo FinanceNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace - Yahoo Finance
finance.yahoo.com - November 13 at 7:40 PM
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace - PRNewswireNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace - PRNewswire
www.prnewswire.com - November 13 at 9:38 AM
BRIEF-Novartis cites positive data for Cosentyx in axial spondyloarthritis - ReutersBRIEF-Novartis cites positive data for Cosentyx in axial spondyloarthritis - Reuters
www.reuters.com - November 12 at 7:38 AM
Novartis: Phase III PREVENT Trial Met Primary Endpoint Of ASAS40 At Week 16 - NasdaqNovartis: Phase III PREVENT Trial Met Primary Endpoint Of ASAS40 At Week 16 - Nasdaq
www.nasdaq.com - November 12 at 7:38 AM
New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis - GlobeNewswireNew Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis - GlobeNewswire
www.globenewswire.com - November 12 at 7:38 AM
UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target - Yahoo FinanceUPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target - Yahoo Finance
finance.yahoo.com - November 11 at 9:31 AM
Novartiss Sandoz generics unit buying Aspens Japanese operations - ReutersNovartis's Sandoz generics unit buying Aspen's Japanese operations - Reuters
www.reuters.com - November 11 at 4:30 AM
UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target - ReutersUPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target - Reuters
www.reuters.com - November 11 at 4:30 AM
Novartis buys Aspens Japanese generic unit for up to 400 million euros - ReutersNovartis buys Aspen's Japanese generic unit for up to 400 million euros - Reuters
www.reuters.com - November 11 at 4:30 AM
ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS - Yahoo FinanceROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS - Yahoo Finance
finance.yahoo.com - November 10 at 1:14 AM
Does Novartis (VTX:NOVN) Have A Healthy Balance Sheet? - Yahoo FinanceDoes Novartis (VTX:NOVN) Have A Healthy Balance Sheet? - Yahoo Finance
finance.yahoo.com - November 5 at 6:47 PM
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel